Diagnostic value of the REM sleep behavior disorder screening questionnaire in Parkinson's disease

Sleep Med. 2015 Jan;16(1):186-9. doi: 10.1016/j.sleep.2014.08.014. Epub 2014 Nov 13.

Abstract

Objective: We aimed to validate the rapid eye movement (REM) sleep behavior disorder (RBD) screening questionnaire (RBDSQ) in 2 independent samples of patients with Parkinson's disease (PD) using different settings when performing the investigations.

Methods: The RBDSQ was administered to two independent samples of 52 and 75 consecutive PD patients investigated with video-polysomnography (vPSG).

Results: In sample A, the RBDSQ identified 46/52 (88.5%) patients correctly. In sample B, 50/75 (66.7%) patients were identified correctly. Considering a cut-off score of ≥ 5 as a positive test result, sample A showed a sensitivity of 0.90 and a specificity of 0.87, sample B showed a sensitivity of 0.68 and a specificity of 0.63. Main differences between both groups were that patients of sample A underwent a sleep history including RBD assessment prior to administration of the RBDSQ, whereas in sample B the RBDSQ was administered during routine work-up.

Conclusions: The diagnostic value of the RBDSQ strongly depends on the clinical setting and may be influenced by the individual's awareness on RBD. This finding is a critical issue which deserves clarification before use of this and other questionnaires can be recommended in epidemiological studies.

Keywords: Disease awareness; Parkinson's disease; REM sleep behavior disorder; Screening questionnaire; Sensitivity; Specificity.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antiparkinson Agents / therapeutic use
  • Cohort Studies
  • Female
  • Humans
  • Male
  • Middle Aged
  • Parkinson Disease / complications*
  • Parkinson Disease / drug therapy
  • Polysomnography
  • Predictive Value of Tests
  • REM Sleep Behavior Disorder / diagnosis*
  • REM Sleep Behavior Disorder / etiology
  • ROC Curve
  • Reproducibility of Results
  • Surveys and Questionnaires*

Substances

  • Antiparkinson Agents